{
    "clinical_study": {
        "@rank": "53827", 
        "arm_group": [
            {
                "arm_group_label": "Angiogenic Cell Precursors", 
                "arm_group_type": "Active Comparator", 
                "description": "Intra-muscular injections of Angiogenic Cell Precursors (ACPs) in the ischemic leg"
            }, 
            {
                "arm_group_label": "Cell culture medium", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intra-muscular injections of cell culture medium in the ischemic leg"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized, double-blind placebo controlled study to determine the safety and efficacy of\n      Angiogenic Cell Precursors (ACPs) in relieving symptoms of Critical Limb Ischemia in\n      patients treated with standard of care and with no surgical revascularization option. It is\n      assumed that the ACP-treated group will have a lower amputation and death rate as compared\n      to the placebo group. Other hemodynamic, imaging and clinical parameters will also be\n      compared between the two groups. Quality of life assessments will also be performed."
        }, 
        "brief_title": "A Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Critical Limb Ischemia", 
        "condition_browse": {
            "mesh_term": "Ischemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is diagnosed with critical limb ischemia\n\n          -  Patient has hemodynamic indicators of severe peripheral arterial disease\n\n          -  Patient is not a candidate for revascularization treatment options for peripheral\n             arterial disease\n\n          -  Patient is on standard of care medical therapy for peripheral arterial disease\n\n          -  Male or female age 18 and above\n\n          -  Non-pregnant, non-lactating female\n\n          -  Patient is able to understand and provide a signed informed consent form\n\n        Exclusion Criteria:\n\n          -  Patient having an uncorrected Aorto-Iliac occlusive disease down to the origin of the\n             Profunda-Femoris artery\n\n          -  Patient who in the opinion of the investigator would require a major amputation\n             within approximately 4 weeks after administration of study treatment.\n\n          -  Critical Limb Ischemia presenting as severe large ischemic ulcers or dry gangrene\n             proximal to the MTP (Metatarsophalangeal) joints heads or lower extremity wet\n             gangrene\n\n          -  Lower extremity non-treated active infection\n\n          -  Hypercoagulable state\n\n          -  Patient received blood transfusions during the previous 4 weeks\n\n          -  Patient's condition precludes 2 consecutive attempts of ACPs manufacturing\n\n          -  Patient unable to communicate\n\n          -  Major non-vascular operation during the preceding 3 months\n\n          -  Myocardial infarction or uncontrolled myocardial ischemia or persistent severe heart\n             failure during the preceding 3 months\n\n          -  Severe aortic stenosis\n\n          -  Severe renal failure\n\n          -  Severe hepatic failure\n\n          -  Anemia\n\n          -  Major stroke within the preceding 3 months.\n\n          -  Diagnosis of malignancy within the preceding 3 years\n\n          -  Concurrent chronic or acute infectious disease and uncontrolled infectious symptoms\n\n          -  Severe concurrent disease\n\n          -  Bleeding diathesis.\n\n          -  Participation at the same time in another stem cell study\n\n          -  Chronic immunomodulating or cytotoxic drug treatment\n\n          -  Fever for 2 days prior to the time the patient is about to receive the study\n             treatment\n\n          -  Life expectancy of less than 6 months\n\n          -  Patient unlikely to be available for follow-up\n\n          -  No acute worsening of CLI (Critical Limb Ischemia)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140931", 
            "org_study_id": "HS 12-01"
        }, 
        "intervention": {
            "arm_group_label": "Angiogenic Cell Precursors", 
            "intervention_name": "Angiogenic Cell Precursors", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cell therapy", 
            "Autologous"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "Hemostemix web site", 
            "url": "http://www.hemostemix.com/"
        }, 
        "location": [
            {
                "contact": {
                    "email": "york.hsiang@vch.ca", 
                    "last_name": "York N. Hsiang, MB ChB MHSc", 
                    "phone": "604.876.5882"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 1K3"
                    }, 
                    "name": "Vancouver General Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "thomas.lindsay@uhn.on.ca", 
                    "last_name": "Thomas F. Lindsy, MDCM Msc BSc", 
                    "phone": "416.340.4800", 
                    "phone_ext": "4620"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2C4"
                    }, 
                    "name": "Toronto General Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "alomranm@smh.ca", 
                    "last_name": "Mohammed Al-Omran, MD MSc", 
                    "phone": "416-864-6047"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5B 1W8"
                    }, 
                    "name": "St. Michael's Hospital"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia", 
        "other_outcome": {
            "description": "Vital signs\nPhysical examination\nClinical laboratory values\nElectrocardiograms\nAdverse events", 
            "measure": "Safety of intramuscular injection of ACPs", 
            "safety_issue": "Yes", 
            "time_frame": "26 weeks"
        }, 
        "overall_contact": {
            "email": "ebraude@hemostemix.com", 
            "last_name": "Eli Braude, MD", 
            "phone": "+972.54.9020120"
        }, 
        "overall_contact_backup": {
            "email": "valentin@hemostemix.com", 
            "last_name": "Valentin Fulga, MD", 
            "phone": "1.416.720.0573"
        }, 
        "overall_official": [
            {
                "affiliation": "Toronto General Hospital", 
                "last_name": "Thomas F. Lindsay, MDCM Msc BSc", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "St. Michael's Hospital, Toronto", 
                "last_name": "Mohammed Al-Omran, MD, MSc", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Vancouver General Hospital", 
                "last_name": "York N. Hsiang, MB ChB MHSc", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to major amputation / mortality", 
            "safety_issue": "No", 
            "time_frame": "26 weeks"
        }, 
        "reference": [
            {
                "PMID": "23993298", 
                "citation": "Szab\u00f3 GV, K\u00f6vesd Z, Cserepes J, Dar\u00f3czy J, Belkin M, Acs\u00e1dy G. Peripheral blood-derived autologous stem cell therapy for the treatment of patients with late-stage peripheral artery disease-results of the short- and long-term follow-up. Cytotherapy. 2013 Oct;15(10):1245-52. doi: 10.1016/j.jcyt.2013.05.017."
            }, 
            {
                "PMID": "17052254", 
                "citation": "Porat Y, Porozov S, Belkin D, Shimoni D, Fisher Y, Belleli A, Czeiger D, Silverman WF, Belkin M, Battler A, Fulga V, Savion N. Isolation of an adult blood-derived progenitor cell population capable of differentiation into angiogenic, myocardial and neural lineages. Br J Haematol. 2006 Dec;135(5):703-14."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140931"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in the level of pain in the treated ischemic leg", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "measure": "Change from baseline in the quantity of analgesic drugs used by the patient", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "measure": "Change from baseline in ABI (Ankle Brachial Index)", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "measure": "Change from baseline  in TBI (Toe Brachial Index)", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "measure": "Change from baseline in quality of life", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "measure": "Change from baseline in ulcer size", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "measure": "Total hospitalization time of ACP-treated patients compared to controls", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }
        ], 
        "source": "Hemostemix", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hemostemix", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}